Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions. The Seed and Integrated Products segment is responsible for creating and bringing to market cutting-edge seed technologies, genetic material, biotechnological innovations, and specialized seed coatings. Under its Crop Protection segment, the company formulates, manufactures, and distributes a comprehensive array of products, including Rizoderma, various adjuvants, therapeutic agents, weed killers, insect eradicators, fungal treatments, and pest lures. The Crop Nutrition unit focuses on the development, production, and distribution of inoculants, bio-stimulants, and both organic and micro-granular fertilizers. A notable offering from Bioceres is HB4, an innovative seed technology engineered for drought resistance. The enterprise maintains a significant presence across several countries, including Argentina, Uruguay, France, and South Africa, alongside broader international operations. Established in 2001, the firm's main offices are situated in Rosario, Argentina. Bioceres Crop Solutions Corp. functions as a subsidiary entity under the umbrella of Bioceres LLC.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is neutral on EV/EBITDA, underpriced on P/FC.